An interventional study of QLB and PCA in Pain, Postoperative and Chronic Postoperative Pain, sponsored by Medical University of Lublin. Completed at 2 sites in Poland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-11-24.
Sponsored by Medical University of Lublin · Not applicable, Interventional, and Treatment
Oxycodone consumption and postoperative pain intensity in patients undergoing nephrectomy procedures. Of all study participants, 50% will obtain quadratus lumborum block (QLB).
Patients undergoing nephrectomy procedures will be allocated to one of the study arms. At the end of an operation, still under general anesthesia, 50% patients will obtain QLB with ropivacaine.
Ultrasound-guided QLB will be performed on the side of surgery with 0.375% ropivacaine solution (0.2 mL per kg).
Every patient will get patient-controlled analgesia pump with oxycodone in the postoperative period.
Postoperative pain will be measured with VAS (visual-analogue scale) 2, 4, 8, 12 and 24 hours after the end of the operation. 24 -hours period.
At the 1, 3, 6 months patients will be interviewed by phone to assess neuropathic pain. Neuropathic Pain Symptom Inventory (NPSI) will be used.
5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.
This study's enrollment of 105 is above the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.
Browse Pain, Postoperative studies →Medical University of Lublin is the lead sponsor of 60 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
At the end of surgery, QLB with ropivacaine will be done on the side of the operation.
Procedure: QLB · Device: PCA · Procedure: GA · Drug: Oxycodone · Drug: Sevoflurane · Drug: Fentanyl · Drug: Rocuronium
Standard care. No regional blocks.
Device: PCA · Procedure: GA · Drug: Oxycodone · Drug: Sevoflurane · Drug: Fentanyl · Drug: Rocuronium
On the side of the surgery, QLB with 0.375% ropivacaine (0.2 mL/kg)
Patient-controlled analgesia
General anesthesia
administered by PCA
Inhalational anesthetic during GA
painkiller during GA
muscle relaxant during GA
Total consumption of oxycodone
Overall use of oxycodone administered by PCA pump will be assessed.
Time frame: 24 hours after the end of surgery.
Pain intensity
Pain intensity measured on VAS scale at the 2, 4, 8, 12, 24 hours. VAS in milimmeters. Minimum value 0, maximum 100. Less better - less severe pain. 0 no pain at all.
Time frame: 24 hours after the end of surgery
Chronic pain
Chronic pain occurrence assessed with Neuropathic Pain Symptom Inventory (NPSI) 10 descriptive variables, each one from 0 to 10. 0 means no pain. 10 very high chance of occurrence of neuropathic pain.
Time frame: 6 months after the surgery
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Lublin